- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Wave Life Sciences Ltd (WVE)
Wave Life Sciences Ltd stock price live, this page displays NASDAQ WVE stock exchange data. View the WVE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Wave Life Sciences Ltd real time stock price chart below.
What Is the Wave Life Sciences Ltd Stock Price Today?
The Wave Life Sciences Ltd stock price today is 13.050.
What Is the Stock Symbol for Wave Life Sciences Ltd?
The stock symbol for Wave Life Sciences Ltd is "WVE."
What Stock Exchange Does Wave Life Sciences Ltd Trade On?
Wave Life Sciences Ltd is listed and trades on the NASDAQ stock exchange.
Is Wave Life Sciences Ltd a Good Stock to Buy?
Determining whether Wave Life Sciences Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the WVE quote. (ISIN: SG9999014716)
What Is the Wave Life Sciences Ltd Stock Price Today?
The Wave Life Sciences Ltd stock price today is 13.050.
What Is the Stock Symbol for Wave Life Sciences Ltd?
The stock symbol for Wave Life Sciences Ltd is "WVE."
What Stock Exchange Does Wave Life Sciences Ltd Trade On?
Wave Life Sciences Ltd is listed and trades on the NASDAQ stock exchange.
Is Wave Life Sciences Ltd a Good Stock to Buy?
Determining whether Wave Life Sciences Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the WVE quote. (ISIN: SG9999014716)
13.135
+0.015(+0.11%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.660
13.510
52 wk Range
5.280
21.730
WVE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.66013.510
52 wk Range
5.28021.730
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
WVE Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
33.500
Upside
+155.04%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Wave Life Sciences Ltd SWOT Analysis
RNA Editing Pionee | Wave Life Sciences leads in RNA editing oligonucleotides, targeting genetic diseases with a diverse pipeline and promising early-stage results in key programs |
AATD Breakthrough | Explore WVE-006's potential for monthly dosing in alpha-1 antitrypsin deficiency, with favorable regulatory pathways and encouraging safety data |
Obesity Market Entry | Delve into Wave's unique INHBE-targeting approach for obesity treatment, offering potential yearly dosing and differentiation in a competitive landscape |
Financial Outlook | Analyst price targets range from $9 to $36, with a consensus "Strong Buy" recommendation despite near-term profitability challenges |
Wave Life Sciences Ltd Earnings Call Summary for Q4/2025
- Q4 2025 revenue fell 79.5% YoY to $17.2M following Takeda collaboration termination in October 2024; EPS loss of $0.30 missed forecast.
- Full-year 2025 revenue declined to $42.7M from $108.3M in 2024; company maintains strong cash position of $602.1M with runway into Q3 2028.
- Stock rose 0.28% in pre-market trading despite EPS miss; shares up 46% over six months but down 14% year-to-date amid high volatility.
- Company focuses on advancing RNA editing pipeline programs and anticipates additional milestone payments from GSK collaboration to strengthen finances.
- Management emphasizes strategic partnerships while navigating challenges from lost Takeda revenue and increased R&D expenses in competitive biotech sector.
Last Updated: 02/26/2026, 11:10 PM
Read Full TranscriptCompare WVE to Peers and Sector
Metrics to compare | WVE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipWVEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.0x | 4.0x | −0.5x | |
PEG Ratio | 0.17 | −0.06 | 0.00 | |
Price/Book | 4.7x | 2.0x | 2.6x | |
Price / LTM Sales | 57.3x | 6.2x | 3.2x | |
Upside (Analyst Target) | 155.3% | 61.9% | 51.2% | |
Fair Value Upside | Unlock | −4.9% | 7.3% | Unlock |
Analyst Ratings
16 Buy
0 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 33.500
(+155.04% Upside)
Earnings
Latest Release
Feb 26, 2026
EPS / Forecast
-0.30 / -0.27
Revenue / Forecast
17.24M / 17.16M
People Also Watch
FAQ
What Is the Wave Life Sciences Ltd (WVE) Stock Price Today?
The Wave Life Sciences Ltd stock price today is 13.135 USD.
What Stock Exchange Does Wave Life Sciences Ltd Trade On?
Wave Life Sciences Ltd is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Wave Life Sciences Ltd?
The stock symbol for Wave Life Sciences Ltd is "WVE."
What Is the Wave Life Sciences Ltd Market Cap?
As of today, Wave Life Sciences Ltd market cap is 2.450B USD.
What Is Wave Life Sciences Ltd's Earnings Per Share (TTM)?
The Wave Life Sciences Ltd EPS (TTM) is -1.212.
When Is the Next Wave Life Sciences Ltd Earnings Date?
Wave Life Sciences Ltd will release its next earnings report on May 07, 2026.
From a Technical Analysis Perspective, Is WVE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Wave Life Sciences Ltd Stock Split?
Wave Life Sciences Ltd has split 0 times.
How Many Employees Does Wave Life Sciences Ltd Have?
Wave Life Sciences Ltd has 317 employees.
What is the current trading status of Wave Life Sciences Ltd (WVE)?
As of Mar 09, 2026, Wave Life Sciences Ltd (WVE) is trading at a price of 13.135 USD, with a previous close of 13.120 USD. The stock has fluctuated within a day range of 12.660 USD to 13.510 USD, while its 52-week range spans from 5.280 USD to 21.730 USD.
What Is Wave Life Sciences Ltd (WVE) Price Target According to Analysts?
The average 12-month price target for Wave Life Sciences Ltd is 33.500 USD, with a high estimate of 50 USD and a low estimate of 22 USD. 16 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +155.04% Upside potential.
What Is the WVE Premarket Price?
WVE's last pre-market stock price is 13.050 USD. The pre-market share volume is 4,770.000, and the stock has decreased by -0.070, or -0.530%.
What Is the WVE After Hours Price?
WVE's last after hours stock price is 13.070 USD, the stock has decreased by -0.050, or -0.380%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.